echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Active Ingredient News > Drugs Articles > How difficult is it for Seretide's generic drug to be marketed?

    How difficult is it for Seretide's generic drug to be marketed?

    • Last Update: 2021-07-11
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com

           Recently, Hengrui issued an announcement stating that in accordance with the latest policy of the State Food and Drug Administration on drug review and approval, combined with the company's actual situation, it has submitted to the State Food and Drug Administration an application for withdrawal of salmeterol ticasone powder inhalation drug registration
    .

           (Source: Juchao Information Network)

           Hengrui stated that the withdrawal is based on the adjustment of the company's internal R&D program
    .
    After the subsequent completion of the BE experiment, Hengrui will re-apply according to category 4 of the new chemical drug registration classification

    .

           No generic drugs are listed in China

           Salmeterol ticasone powder inhalation in the form of a combination (bronchodilator and inhaled corticosteroids) is intended for the regular treatment of reversible airway obstructive airway diseases, including asthma in adults and children
    .
    Salmeterol and fluticasone propionate powder inhalation contains salmeterol and fluticasone propionate, which have different modes of action.
    Salmeterol can control symptoms, while fluticasone propionate can improve lung function and prevent disease deterioration.
    Both The combination can provide a more convenient solution for patients who are treated with β-agonists and inhaled corticosteroids at the same time

    .

           Salmeterol ticasone powder inhalation was developed by GSK.
    It was first marketed in the UK in March 1999 and was approved by the US FDA in August 2000 under the trade name Advair Diskus

    .

           In 2001, salmeterol ticasone powder inhalation was approved to enter the Chinese market, and its indication was chronic obstructive pulmonary disease (COPD), and its trade name was seretide; in 2010, a new indication for asthma was added in China
    .
    According to the Evaluate Pharma database, Seretide's sales in the global market have been declining in recent years, with global sales of US$2.
    807 billion in 2020

    .
    The domestic market is showing an upward trend.
    In 2019, the sales of domestic sample hospitals were 281 million yuan

    .

           In 2013, the seretide compound patent expired in China
    .
    At present, domestic companies such as Chia Tai Tianqing, Hengrui, Tianjin Xinnuo, Prit, and Runsheng Pharmaceutical have submitted listing applications

    .

           (Source: CDE official website)

           However, since Seretide is a combination product of medicine and equipment, the development of such inhaler generic products is far more difficult than that of oral solid preparations.
    The first generic drug in the world was not approved by the FDA until February 2019.
    Wixela Inhub developed by Mylan

    .
    However, domestic generic drugs have not yet been approved

    .

           It is worth mentioning that CP Tianqing’s salmeterol inhalation powder mist , which had entered the priority review on the grounds of "major special project", was only one step away from the market
    .
    The drug's marketing application (acceptance number: CYHS1700680, 681) was changed to "approval completed-pending certification" in June 2019.
    The industry once believed that CP Tianqing would win the first copy, but there has been no news of approval for listing since then

    .

           In January of this year, some insiders pointed out that Hengrui's salmeterol ticasone powder inhaler will be approved this year, but now it is unlikely
    .

           Two consecutive pharmaceutical giants have broken down.
    It takes time to test whether Prit, Runsheng Pharmaceutical and Tianjin Cigna can be successfully approved, and which one wins the first imitation

    .
    However, the author wants to emphasize that the withdrawal and the issuance of supplements do not mean that there is no chance to go public.
    CP Tianqing and Hengrui still have a chance to be approved

    .

           Public data shows that in 2019, the global sales of inhaled preparations hospital port was 48 billion U.
    S.
    dollars, and the market size is expected to expand to 59.
    2 billion U.
    S.
    dollars in 2023

    .
    At the same time, the proportion of domestic inhalation preparations is also steadily increasing.
    In 2019, the sales amount of inhalation preparations was 23.
    68 billion yuan.
    According to industry insiders, the market size of terminal inhalation preparations in China's public medical institutions will reach 34.
    67 billion yuan in 2023

    .
    Therefore, the competition for inhaled preparations will become increasingly fierce

    .
           

    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.
    Related Articles

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent Echemi's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.